{"transactions":[{"id":723854,"issuer":{"id":6614,"kind":"organization","name":"vTv Therapeutics Inc."},"owners":[{"id":34781,"kind":"person","name":"SPIEGELMAN DANIEL K","position":1,"cik":"0001238403","reported_name":"SPIEGELMAN DANIEL K","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director stock option (right to buy)","published_at":"2026-06-29T20:10:19.000Z","date":"2026-06-26","kind":"grant","planned":false,"acquired":true,"shares":6000,"price":35.08,"value":210480.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests on the earlier of June 26, 2027, and the date of the 2027 annual general meeting of shareholders, subject to the director's continued service on the board of directors through such vesting."}],"balance_after":16000,"derivative":{"exercise_price":35.08,"expiration_date":"2036-06-26","underlying":"Class A Common Stock","underlying_shares":6000},"source":{"system":"sec-edgar","filing":"0001238403-26-000006","document":"wk-form4_1782763816.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1238403/000123840326000006/wk-form4_1782763816.xml","form_type":"4"}},{"id":742935,"issuer":{"id":1775,"kind":"organization","name":"Maze Therapeutics, Inc.","symbol":"MAZE"},"owners":[{"id":34781,"kind":"person","name":"SPIEGELMAN DANIEL K","position":1,"cik":"0001238403","reported_name":"SPIEGELMAN DANIEL K","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-10T20:31:33.000Z","date":"2026-06-08","kind":"grant","planned":false,"acquired":true,"shares":18000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option shall vest and be fully exercisable on the earlier of (i) the date of the issuer's 2027 annual stockholders meeting or (ii) June 8, 2027, subject to the reporting person's continued service to the issuer on the vesting date."}],"balance_after":18000,"derivative":{"exercise_price":23.58,"expiration_date":"2036-06-07","underlying":"Common Stock","underlying_shares":18000},"source":{"system":"sec-edgar","filing":"0001238403-26-000004","document":"form4-06102026_080629.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1238403/000123840326000004/form4-06102026_080629.xml","form_type":"4"}},{"id":763767,"issuer":{"id":6471,"kind":"organization","name":"SPRUCE BIOSCIENCES, INC."},"owners":[{"id":34781,"kind":"person","name":"SPIEGELMAN DANIEL K","position":1,"cik":"0001238403","reported_name":"SPIEGELMAN DANIEL K","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-05-26T20:30:37.000Z","date":"2026-05-21","kind":"grant","planned":false,"acquired":true,"shares":1700,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares vest on the first anniversary of the Grant Date, provided that the Option will in any case be fully vested on the date of Company's 2027 annual stockholder meeting, subject to the Reporting Person's Continuous Service (as defined in the 2020 Equity Incentive Plan (the \"Plan\")) through such vesting date and will vest in full upon a Change in Control (as defined in the Plan)."}],"balance_after":1700,"derivative":{"exercise_price":52.7,"expiration_date":"2036-05-20","underlying":"Common Stock","underlying_shares":1700},"source":{"system":"sec-edgar","filing":"0001238403-26-000002","document":"form4-05262026_040510.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1683553/000123840326000002/form4-05262026_040510.xml","form_type":"4"}},{"id":969487,"issuer":{"id":6471,"kind":"organization","name":"SPRUCE BIOSCIENCES, INC."},"owners":[{"id":34781,"kind":"person","name":"SPIEGELMAN DANIEL K","position":1,"cik":"0001238403","reported_name":"SPIEGELMAN DANIEL K","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-12-16T00:00:01.000Z","date":"2025-12-11","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":400,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Effective August 4, 2025, the Issuer effected a reverse stock split (the \"Reverse Split\") whereby every seventy-five shares of its issued and outstanding Common Stock were automatically combined into one share of Common Stock. In connection with the Reverse Split, each stock option to purchase 75 shares of Common Stock was automatically combined into a stock option to purchase one share of Common Stock and the exercise prices of such options were multiplied by seventy-five."},{"field":"shares","element":"transactionShares","label":"F1","text":"Effective August 4, 2025, the Issuer effected a reverse stock split (the \"Reverse Split\") whereby every seventy-five shares of its issued and outstanding Common Stock were automatically combined into one share of Common Stock. In connection with the Reverse Split, each stock option to purchase 75 shares of Common Stock was automatically combined into a stock option to purchase one share of Common Stock and the exercise prices of such options were multiplied by seventy-five."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The transactions reported herein reflect a one-time stock option repricing (the \"Option Repricing\") effective on December 11, 2025 (the \"Repricing Date\"). The Option Repricing applies to options with exercise prices of $106.09 per share or greater held by employees and directors of the Issuer who remained in continuous service with the Company as of the Repricing Date."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the Option Repricing, the exercise price of the repriced options has been amended to reduce the exercise price to $104.13 per share, the thirty (30)-day trailing volume-weighted average price of the Common Stock on the Nasdaq Capital Market on the Repricing Date. However, if an optionholder exercises a repriced option before the end of a retention period of one year (which period may be shorter in certain circumstances), such optionholder will be required to pay the original exercise price per share of such repriced option. No other changes were made to the repriced options in connection with the Option Repricing, including with respect to the vesting schedules, expiration dates or number of shares underlying such repriced options."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares subject to the option are fully vested and exercisable."}],"balance_after":0,"derivative":{"exercise_price":169.5,"expiration_date":"2033-05-24","underlying":"Common Stock","underlying_shares":400},"source":{"system":"sec-edgar","filing":"0001238403-25-000007","document":"form4-12152025_111257.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1683553/000123840325000007/form4-12152025_111257.xml","form_type":"4"}},{"id":969486,"issuer":{"id":6471,"kind":"organization","name":"SPRUCE BIOSCIENCES, INC."},"owners":[{"id":34781,"kind":"person","name":"SPIEGELMAN DANIEL K","position":1,"cik":"0001238403","reported_name":"SPIEGELMAN DANIEL K","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-12-16T00:00:01.000Z","date":"2025-12-11","kind":"grant","planned":false,"acquired":true,"shares":400,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Effective August 4, 2025, the Issuer effected a reverse stock split (the \"Reverse Split\") whereby every seventy-five shares of its issued and outstanding Common Stock were automatically combined into one share of Common Stock. In connection with the Reverse Split, each stock option to purchase 75 shares of Common Stock was automatically combined into a stock option to purchase one share of Common Stock and the exercise prices of such options were multiplied by seventy-five."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The transactions reported herein reflect a one-time stock option repricing (the \"Option Repricing\") effective on December 11, 2025 (the \"Repricing Date\"). The Option Repricing applies to options with exercise prices of $106.09 per share or greater held by employees and directors of the Issuer who remained in continuous service with the Company as of the Repricing Date."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the Option Repricing, the exercise price of the repriced options has been amended to reduce the exercise price to $104.13 per share, the thirty (30)-day trailing volume-weighted average price of the Common Stock on the Nasdaq Capital Market on the Repricing Date. However, if an optionholder exercises a repriced option before the end of a retention period of one year (which period may be shorter in certain circumstances), such optionholder will be required to pay the original exercise price per share of such repriced option. No other changes were made to the repriced options in connection with the Option Repricing, including with respect to the vesting schedules, expiration dates or number of shares underlying such repriced options."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares subject to the option are fully vested and exercisable."}],"balance_after":400,"derivative":{"exercise_price":104.13,"expiration_date":"2033-05-24","underlying":"Common Stock","underlying_shares":400},"source":{"system":"sec-edgar","filing":"0001238403-25-000007","document":"form4-12152025_111257.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1683553/000123840325000007/form4-12152025_111257.xml","form_type":"4"}},{"id":969485,"issuer":{"id":6471,"kind":"organization","name":"SPRUCE BIOSCIENCES, INC."},"owners":[{"id":34781,"kind":"person","name":"SPIEGELMAN DANIEL K","position":1,"cik":"0001238403","reported_name":"SPIEGELMAN DANIEL K","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-12-16T00:00:01.000Z","date":"2025-12-11","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":88,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Effective August 4, 2025, the Issuer effected a reverse stock split (the \"Reverse Split\") whereby every seventy-five shares of its issued and outstanding Common Stock were automatically combined into one share of Common Stock. In connection with the Reverse Split, each stock option to purchase 75 shares of Common Stock was automatically combined into a stock option to purchase one share of Common Stock and the exercise prices of such options were multiplied by seventy-five."},{"field":"shares","element":"transactionShares","label":"F1","text":"Effective August 4, 2025, the Issuer effected a reverse stock split (the \"Reverse Split\") whereby every seventy-five shares of its issued and outstanding Common Stock were automatically combined into one share of Common Stock. In connection with the Reverse Split, each stock option to purchase 75 shares of Common Stock was automatically combined into a stock option to purchase one share of Common Stock and the exercise prices of such options were multiplied by seventy-five."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The transactions reported herein reflect a one-time stock option repricing (the \"Option Repricing\") effective on December 11, 2025 (the \"Repricing Date\"). The Option Repricing applies to options with exercise prices of $106.09 per share or greater held by employees and directors of the Issuer who remained in continuous service with the Company as of the Repricing Date."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the Option Repricing, the exercise price of the repriced options has been amended to reduce the exercise price to $104.13 per share, the thirty (30)-day trailing volume-weighted average price of the Common Stock on the Nasdaq Capital Market on the Repricing Date. However, if an optionholder exercises a repriced option before the end of a retention period of one year (which period may be shorter in certain circumstances), such optionholder will be required to pay the original exercise price per share of such repriced option. No other changes were made to the repriced options in connection with the Option Repricing, including with respect to the vesting schedules, expiration dates or number of shares underlying such repriced options."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares subject to the option are fully vested and exercisable."}],"balance_after":0,"derivative":{"exercise_price":1143,"expiration_date":"2031-05-19","underlying":"Common Stock","underlying_shares":88},"source":{"system":"sec-edgar","filing":"0001238403-25-000007","document":"form4-12152025_111257.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1683553/000123840325000007/form4-12152025_111257.xml","form_type":"4"}},{"id":969484,"issuer":{"id":6471,"kind":"organization","name":"SPRUCE BIOSCIENCES, INC."},"owners":[{"id":34781,"kind":"person","name":"SPIEGELMAN DANIEL K","position":1,"cik":"0001238403","reported_name":"SPIEGELMAN DANIEL K","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-12-16T00:00:01.000Z","date":"2025-12-11","kind":"grant","planned":false,"acquired":true,"shares":88,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Effective August 4, 2025, the Issuer effected a reverse stock split (the \"Reverse Split\") whereby every seventy-five shares of its issued and outstanding Common Stock were automatically combined into one share of Common Stock. In connection with the Reverse Split, each stock option to purchase 75 shares of Common Stock was automatically combined into a stock option to purchase one share of Common Stock and the exercise prices of such options were multiplied by seventy-five."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The transactions reported herein reflect a one-time stock option repricing (the \"Option Repricing\") effective on December 11, 2025 (the \"Repricing Date\"). The Option Repricing applies to options with exercise prices of $106.09 per share or greater held by employees and directors of the Issuer who remained in continuous service with the Company as of the Repricing Date."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the Option Repricing, the exercise price of the repriced options has been amended to reduce the exercise price to $104.13 per share, the thirty (30)-day trailing volume-weighted average price of the Common Stock on the Nasdaq Capital Market on the Repricing Date. However, if an optionholder exercises a repriced option before the end of a retention period of one year (which period may be shorter in certain circumstances), such optionholder will be required to pay the original exercise price per share of such repriced option. No other changes were made to the repriced options in connection with the Option Repricing, including with respect to the vesting schedules, expiration dates or number of shares underlying such repriced options."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares subject to the option are fully vested and exercisable."}],"balance_after":88,"derivative":{"exercise_price":104.13,"expiration_date":"2031-05-19","underlying":"Common Stock","underlying_shares":88},"source":{"system":"sec-edgar","filing":"0001238403-25-000007","document":"form4-12152025_111257.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1683553/000123840325000007/form4-12152025_111257.xml","form_type":"4"}},{"id":969483,"issuer":{"id":6471,"kind":"organization","name":"SPRUCE BIOSCIENCES, INC."},"owners":[{"id":34781,"kind":"person","name":"SPIEGELMAN DANIEL K","position":1,"cik":"0001238403","reported_name":"SPIEGELMAN DANIEL K","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-12-16T00:00:01.000Z","date":"2025-12-11","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":458,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Effective August 4, 2025, the Issuer effected a reverse stock split (the \"Reverse Split\") whereby every seventy-five shares of its issued and outstanding Common Stock were automatically combined into one share of Common Stock. In connection with the Reverse Split, each stock option to purchase 75 shares of Common Stock was automatically combined into a stock option to purchase one share of Common Stock and the exercise prices of such options were multiplied by seventy-five."},{"field":"shares","element":"transactionShares","label":"F1","text":"Effective August 4, 2025, the Issuer effected a reverse stock split (the \"Reverse Split\") whereby every seventy-five shares of its issued and outstanding Common Stock were automatically combined into one share of Common Stock. In connection with the Reverse Split, each stock option to purchase 75 shares of Common Stock was automatically combined into a stock option to purchase one share of Common Stock and the exercise prices of such options were multiplied by seventy-five."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The transactions reported herein reflect a one-time stock option repricing (the \"Option Repricing\") effective on December 11, 2025 (the \"Repricing Date\"). The Option Repricing applies to options with exercise prices of $106.09 per share or greater held by employees and directors of the Issuer who remained in continuous service with the Company as of the Repricing Date."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the Option Repricing, the exercise price of the repriced options has been amended to reduce the exercise price to $104.13 per share, the thirty (30)-day trailing volume-weighted average price of the Common Stock on the Nasdaq Capital Market on the Repricing Date. However, if an optionholder exercises a repriced option before the end of a retention period of one year (which period may be shorter in certain circumstances), such optionholder will be required to pay the original exercise price per share of such repriced option. No other changes were made to the repriced options in connection with the Option Repricing, including with respect to the vesting schedules, expiration dates or number of shares underlying such repriced options."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares subject to the option are fully vested and exercisable."}],"balance_after":0,"derivative":{"exercise_price":564,"expiration_date":"2030-09-08","underlying":"Common Stock","underlying_shares":458},"source":{"system":"sec-edgar","filing":"0001238403-25-000007","document":"form4-12152025_111257.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1683553/000123840325000007/form4-12152025_111257.xml","form_type":"4"}},{"id":969482,"issuer":{"id":6471,"kind":"organization","name":"SPRUCE BIOSCIENCES, INC."},"owners":[{"id":34781,"kind":"person","name":"SPIEGELMAN DANIEL K","position":1,"cik":"0001238403","reported_name":"SPIEGELMAN DANIEL K","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-12-16T00:00:01.000Z","date":"2025-12-11","kind":"grant","planned":false,"acquired":true,"shares":458,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Effective August 4, 2025, the Issuer effected a reverse stock split (the \"Reverse Split\") whereby every seventy-five shares of its issued and outstanding Common Stock were automatically combined into one share of Common Stock. In connection with the Reverse Split, each stock option to purchase 75 shares of Common Stock was automatically combined into a stock option to purchase one share of Common Stock and the exercise prices of such options were multiplied by seventy-five."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The transactions reported herein reflect a one-time stock option repricing (the \"Option Repricing\") effective on December 11, 2025 (the \"Repricing Date\"). The Option Repricing applies to options with exercise prices of $106.09 per share or greater held by employees and directors of the Issuer who remained in continuous service with the Company as of the Repricing Date."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the Option Repricing, the exercise price of the repriced options has been amended to reduce the exercise price to $104.13 per share, the thirty (30)-day trailing volume-weighted average price of the Common Stock on the Nasdaq Capital Market on the Repricing Date. However, if an optionholder exercises a repriced option before the end of a retention period of one year (which period may be shorter in certain circumstances), such optionholder will be required to pay the original exercise price per share of such repriced option. No other changes were made to the repriced options in connection with the Option Repricing, including with respect to the vesting schedules, expiration dates or number of shares underlying such repriced options."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares subject to the option are fully vested and exercisable."}],"balance_after":458,"derivative":{"exercise_price":104.13,"expiration_date":"2030-09-08","underlying":"Common Stock","underlying_shares":458},"source":{"system":"sec-edgar","filing":"0001238403-25-000007","document":"form4-12152025_111257.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1683553/000123840325000007/form4-12152025_111257.xml","form_type":"4"}},{"id":1032929,"issuer":{"id":1775,"kind":"organization","name":"Maze Therapeutics, Inc.","symbol":"MAZE"},"owners":[{"id":34781,"kind":"person","name":"SPIEGELMAN DANIEL K","position":1,"cik":"0001238403","reported_name":"SPIEGELMAN DANIEL K","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-09-24T20:21:04.000Z","date":"2025-09-22","kind":"grant","planned":false,"acquired":true,"shares":18000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option shall vest as to 1/9 of the total award monthly with the first tranche vesting on October 1, 2025, subject to the reporting person's continued service to the Issuer on the applicable vesting date."}],"balance_after":18000,"derivative":{"exercise_price":23.67,"expiration_date":"2035-09-21","underlying":"Common Stock","underlying_shares":18000},"source":{"system":"sec-edgar","filing":"0001238403-25-000005","document":"form4-09242025_080900.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1238403/000123840325000005/form4-09242025_080900.xml","form_type":"4"}},{"id":1082147,"issuer":{"id":6471,"kind":"organization","name":"SPRUCE BIOSCIENCES, INC."},"owners":[{"id":34781,"kind":"person","name":"SPIEGELMAN DANIEL K","position":1,"cik":"0001238403","reported_name":"SPIEGELMAN DANIEL K","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-07-24T23:38:45.000Z","date":"2025-07-22","kind":"grant","planned":false,"acquired":true,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares vest on the first anniversary of the Grant Date, provided that the Option will in any case be fully vested on the date of Company's 2026 annual stockholder meeting, subject to the Reporting Person's Continuous Service (as defined in the 2020 Equity Incentive Plan (the \"Plan\")) through such vesting date and will vest in full upon a Change in Control (as defined in the Plan)."}],"balance_after":30000,"derivative":{"exercise_price":0.1162,"expiration_date":"2035-07-21","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0001415889-25-020270","document":"form4-07242025_110741.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1683553/000141588925020270/form4-07242025_110741.xml","form_type":"4"}},{"id":1113100,"issuer":{"id":6614,"kind":"organization","name":"vTv Therapeutics Inc."},"owners":[{"id":34781,"kind":"person","name":"SPIEGELMAN DANIEL K","position":1,"cik":"0001238403","reported_name":"SPIEGELMAN DANIEL K","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director stock option (right to buy)","published_at":"2025-06-12T20:28:17.000Z","date":"2025-06-10","kind":"grant","planned":false,"acquired":true,"shares":4000,"price":16.59,"value":66360.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests on the earlier of June 10, 2026, and the date of the 2026 annual general meeting of shareholders, subject to the director's continued service on the board of directors through such vesting."}],"balance_after":10000,"derivative":{"exercise_price":16.59,"expiration_date":"2035-06-10","underlying":"Class A Common Stock","underlying_shares":4000},"source":{"system":"sec-edgar","filing":"0001641489-25-000046","document":"wk-form4_1749760089.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1238403/000164148925000046/wk-form4_1749760089.xml","form_type":"4"}},{"id":1127410,"issuer":{"id":5452,"kind":"organization","name":"Kyverna Therapeutics, Inc."},"owners":[{"id":34781,"kind":"person","name":"SPIEGELMAN DANIEL K","position":1,"cik":"0001238403","reported_name":"SPIEGELMAN DANIEL K","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-06-02T22:35:43.000Z","date":"2025-05-29","kind":"grant","planned":false,"acquired":true,"shares":65351,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"All of the shares subject to the option shall be fully vested and exercisable on the earlier of (i) May 29, 2026, and (ii) immediately prior to the date of the Issuer's 2026 annual meeting of stockholders, subject to the Reporting Person's continuous service to the Issuer on and through each applicable vesting date, inclusive."}],"balance_after":65351,"derivative":{"exercise_price":2.63,"expiration_date":"2035-05-29","underlying":"Common Stock","underlying_shares":65351},"source":{"system":"sec-edgar","filing":"0000950170-25-080456","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1238403/000095017025080456/ownership.xml","form_type":"4"}},{"id":1127409,"issuer":{"id":5452,"kind":"organization","name":"Kyverna Therapeutics, Inc."},"owners":[{"id":34781,"kind":"person","name":"SPIEGELMAN DANIEL K","position":1,"cik":"0001238403","reported_name":"SPIEGELMAN DANIEL K","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-06-02T22:35:43.000Z","date":"2025-05-29","kind":"grant","planned":false,"acquired":true,"shares":16634,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents a restricted stock unit award of common stock, which will vest in full on the earlier of (i) May 29, 2026, and (ii) immediately prior to the date of the Issuer's 2026 annual meeting of stockholders, subject to the Reporting Person's continuous service to the Issuer on and through each applicable vesting date, inclusive."}],"balance_after":16634,"source":{"system":"sec-edgar","filing":"0000950170-25-080456","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1238403/000095017025080456/ownership.xml","form_type":"4"}},{"id":1468028,"issuer":{"id":6614,"kind":"organization","name":"vTv Therapeutics Inc."},"owners":[{"id":34781,"kind":"person","name":"SPIEGELMAN DANIEL K","position":1,"cik":"0001238403","reported_name":"SPIEGELMAN DANIEL K","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director stock option (right to buy)","published_at":"2024-06-27T20:40:22.000Z","date":"2024-06-25","kind":"grant","planned":false,"acquired":true,"shares":6000,"price":17.22,"value":103320.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options will vest monthly over the three year period following date of grant."}],"balance_after":6000,"derivative":{"exercise_price":17.22,"expiration_date":"2034-06-25","underlying":"Class A Common Stock","underlying_shares":6000},"source":{"system":"sec-edgar","filing":"0001641489-24-000051","document":"wk-form4_1719520815.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1238403/000164148924000051/wk-form4_1719520815.xml","form_type":"4"}},{"id":1493630,"issuer":{"id":5953,"kind":"organization","name":"MYRIAD GENETICS INC","symbol":"MYGN"},"owners":[{"id":34781,"kind":"person","name":"SPIEGELMAN DANIEL K","position":1,"cik":"0001238403","reported_name":"SPIEGELMAN DANIEL K","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-06-04T21:57:26.000Z","date":"2024-06-04","kind":"sale","planned":true,"acquired":false,"shares":3788,"price":22.05,"value":83525.4,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan."}],"balance_after":32917,"source":{"system":"sec-edgar","filing":"0001238403-24-000002","document":"wk-form4_1717538237.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/899923/000123840324000002/wk-form4_1717538237.xml","form_type":"4"}},{"id":1493629,"issuer":{"id":5953,"kind":"organization","name":"MYRIAD GENETICS INC","symbol":"MYGN"},"owners":[{"id":34781,"kind":"person","name":"SPIEGELMAN DANIEL K","position":1,"cik":"0001238403","reported_name":"SPIEGELMAN DANIEL K","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-06-04T21:57:26.000Z","date":"2024-06-03","kind":"sale","planned":true,"acquired":false,"shares":3788,"price":22.04,"value":83487.52,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan."}],"balance_after":36705,"source":{"system":"sec-edgar","filing":"0001238403-24-000002","document":"wk-form4_1717538237.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/899923/000123840324000002/wk-form4_1717538237.xml","form_type":"4"}},{"id":1502093,"issuer":{"id":6471,"kind":"organization","name":"SPRUCE BIOSCIENCES, INC."},"owners":[{"id":34781,"kind":"person","name":"SPIEGELMAN DANIEL K","position":1,"cik":"0001238403","reported_name":"SPIEGELMAN DANIEL K","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-05-24T20:28:24.000Z","date":"2024-05-22","kind":"grant","planned":false,"acquired":true,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares vest on the first anniversary of the Grant Date, provided that the Option will in any case be fully vested on the date of Company's 2025 annual stockholder meeting, subject to the Reporting Person's Continuous Service (as defined in the 2020 Equity Incentive Plan (the \"Plan\")) through such vesting date and will vest in full upon a Change in Control (as defined in the Plan)."}],"balance_after":30000,"derivative":{"exercise_price":0.7511,"expiration_date":"2034-05-21","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0001415889-24-014493","document":"form4-05242024_080517.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1683553/000141588924014493/form4-05242024_080517.xml","form_type":"4"}},{"id":1870918,"issuer":{"id":5953,"kind":"organization","name":"MYRIAD GENETICS INC","symbol":"MYGN"},"owners":[{"id":34781,"kind":"person","name":"SPIEGELMAN DANIEL K","position":1,"cik":"0001238403","reported_name":"SPIEGELMAN DANIEL K","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-06-02T22:15:32.000Z","date":"2023-06-02","kind":"sale","planned":false,"acquired":false,"shares":8638,"price":23.01,"value":198760.38,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan."}],"balance_after":40493,"source":{"system":"sec-edgar","filing":"0001238403-23-000002","document":"wk-form4_1685744119.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/899923/000123840323000002/wk-form4_1685744119.xml","form_type":"4"}},{"id":1870917,"issuer":{"id":5953,"kind":"organization","name":"MYRIAD GENETICS INC","symbol":"MYGN"},"owners":[{"id":34781,"kind":"person","name":"SPIEGELMAN DANIEL K","position":1,"cik":"0001238403","reported_name":"SPIEGELMAN DANIEL K","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-06-02T22:15:32.000Z","date":"2023-06-01","kind":"grant","planned":false,"acquired":true,"shares":15151,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Consists of restricted stock units granted pursuant to Myriad Genetics, Inc.'s 2017 Employee, Director and Consultant Equity Incentive Plan. Each restricted stock unit represents a contingent right to receive one share of common stock and vests upon the earlier of (a) the first anniversary of the date of grant and (b) the date of the next annual meeting of stockholders following such grant."}],"balance_after":49131,"source":{"system":"sec-edgar","filing":"0001238403-23-000002","document":"wk-form4_1685744119.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/899923/000123840323000002/wk-form4_1685744119.xml","form_type":"4"}},{"id":1876604,"issuer":{"id":6471,"kind":"organization","name":"SPRUCE BIOSCIENCES, INC."},"owners":[{"id":34781,"kind":"person","name":"SPIEGELMAN DANIEL K","position":1,"cik":"0001238403","reported_name":"SPIEGELMAN DANIEL K","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-05-26T21:40:36.000Z","date":"2023-05-25","kind":"grant","planned":false,"acquired":true,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares vest on the first anniversary of the Grant Date, provided that the Option will in any case be fully vested on the date of Company's 2024 annual stockholder meeting, subject to the Reporting Person's Continuous Service (as defined in the 2020 Equity Incentive Plan (the \"Plan\")) through such vesting date and will vest in full upon a Change in Control (as defined in the Plan)."}],"balance_after":30000,"derivative":{"exercise_price":2.26,"expiration_date":"2033-05-24","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0001209191-23-032663","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1683553/000120919123032663/doc4.xml","form_type":"4"}},{"id":2243047,"issuer":{"id":5953,"kind":"organization","name":"MYRIAD GENETICS INC","symbol":"MYGN"},"owners":[{"id":34781,"kind":"person","name":"SPIEGELMAN DANIEL K","position":1,"cik":"0001238403","reported_name":"SPIEGELMAN DANIEL K","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-06-06T23:20:58.000Z","date":"2022-06-06","kind":"sale","acquired":false,"shares":6424,"price":19.2517,"value":123672.9208,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.01 to $19.57, inclusive. The Reporting Person undertakes to provide to Myriad Genetics, Inc., any security holder of Myriad Genetics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":33980,"source":{"system":"sec-edgar","filing":"0001238403-22-000002","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/899923/000123840322000002/edgardoc.xml","form_type":"4"}},{"id":2246013,"issuer":{"id":5953,"kind":"organization","name":"MYRIAD GENETICS INC","symbol":"MYGN"},"owners":[{"id":34781,"kind":"person","name":"SPIEGELMAN DANIEL K","position":1,"cik":"0001238403","reported_name":"SPIEGELMAN DANIEL K","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-06-03T21:27:43.000Z","date":"2022-06-02","kind":"grant","acquired":true,"shares":17275,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Consists of restricted stock units granted pursuant to Myriad Genetics, Inc.'s 2017 Employee, Director and Consultant Equity Incentive Plan. Each restricted stock unit represents a contingent right to receive one share of common stock and vests upon the earlier of (a) the first anniversary of the Date of Grant and (b) the date of the next annual meeting of stockholders following such grant."}],"balance_after":40404,"source":{"system":"sec-edgar","filing":"0001628280-22-016223","document":"wf-form4_165429164220216.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/899923/000162828022016223/wf-form4_165429164220216.xml","form_type":"4"}},{"id":2253527,"issuer":{"id":6471,"kind":"organization","name":"SPRUCE BIOSCIENCES, INC."},"owners":[{"id":34781,"kind":"person","name":"SPIEGELMAN DANIEL K","position":1,"cik":"0001238403","reported_name":"SPIEGELMAN DANIEL K","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-05-27T20:12:38.000Z","date":"2022-05-25","kind":"grant","acquired":true,"shares":22500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares vest on the first anniversary of the Grant Date, provided that the Option will in any case be fully vested on the date of Company's 2023 annual stockholder meeting, subject to the Reporting Person's Continuous Service (as defined in the 2020 Equity Incentive Plan (the \"Plan\")) through such vesting date and will vest in full upon a Change in Control (as defined in the Plan)."}],"balance_after":22500,"derivative":{"exercise_price":1.32,"expiration_date":"2032-05-24","underlying":"Common Stock","underlying_shares":22500},"source":{"system":"sec-edgar","filing":"0001209191-22-032503","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1683553/000120919122032503/doc4.xml","form_type":"4"}},{"id":2664897,"issuer":{"id":5953,"kind":"organization","name":"MYRIAD GENETICS INC","symbol":"MYGN"},"owners":[{"id":34781,"kind":"person","name":"SPIEGELMAN DANIEL K","position":1,"cik":"0001238403","reported_name":"SPIEGELMAN DANIEL K","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-06-17T21:41:51.000Z","date":"2021-06-17","kind":"sale","acquired":false,"shares":3139,"price":30.5176,"value":95794.7464,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.41 to $30.65, inclusive. The Reporting Person undertakes to provide to Myriad Genetics, Inc., any security holder of Myriad Genetics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":23129,"source":{"system":"sec-edgar","filing":"0001238403-21-000008","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/899923/000123840321000008/edgardoc.xml","form_type":"4"}},{"id":2681731,"issuer":{"id":5953,"kind":"organization","name":"MYRIAD GENETICS INC","symbol":"MYGN"},"owners":[{"id":34781,"kind":"person","name":"SPIEGELMAN DANIEL K","position":1,"cik":"0001238403","reported_name":"SPIEGELMAN DANIEL K","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-06-04T23:11:07.000Z","date":"2021-06-03","kind":"grant","acquired":true,"shares":12848,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Consists of restricted stock units granted pursuant to Myriad Genetics, Inc.'s 2017 Employee, Director and Consultant Equity Incentive Plan. Each restricted stock unit represents a contingent right to receive one share of common stock and vests on the anniversary of the date of grant."}],"balance_after":26268,"source":{"system":"sec-edgar","filing":"0001238403-21-000006","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/899923/000123840321000006/edgardoc.xml","form_type":"4"}},{"id":2689940,"issuer":{"id":5953,"kind":"organization","name":"MYRIAD GENETICS INC","symbol":"MYGN"},"owners":[{"id":34781,"kind":"person","name":"SPIEGELMAN DANIEL K","position":1,"cik":"0001238403","reported_name":"SPIEGELMAN DANIEL K","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-06-01T23:15:40.000Z","date":"2021-05-28","kind":"sale","acquired":false,"shares":7142,"price":28.9867,"value":207023.0114,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.75 to $29.30, inclusive. The Reporting Person undertakes to provide to Myriad Genetics, Inc., any security holder of Myriad Genetics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":13420,"source":{"system":"sec-edgar","filing":"0001238403-21-000004","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/899923/000123840321000004/edgardoc.xml","form_type":"4"}},{"id":2692095,"issuer":{"id":5953,"kind":"organization","name":"MYRIAD GENETICS INC","symbol":"MYGN"},"owners":[{"id":34781,"kind":"person","name":"SPIEGELMAN DANIEL K","position":1,"cik":"0001238403","reported_name":"SPIEGELMAN DANIEL K","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-05-28T22:48:14.000Z","date":"2021-05-27","kind":"disposition_to_issuer","acquired":false,"shares":15889,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On May 27, 2021, the Company rescinded Mr. Spiegelman's grant of 15,889 restricted stock units granted on December 4, 2020 and reported on the Form 4 filed with the Securities and Exchange Commission on December 7, 2020."}],"balance_after":20562,"source":{"system":"sec-edgar","filing":"0001238403-21-000002","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/899923/000123840321000002/edgardoc.xml","form_type":"4"}},{"id":2700956,"issuer":{"id":6471,"kind":"organization","name":"SPRUCE BIOSCIENCES, INC."},"owners":[{"id":34781,"kind":"person","name":"SPIEGELMAN DANIEL K","position":1,"cik":"0001238403","reported_name":"SPIEGELMAN DANIEL K","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-05-22T01:11:36.000Z","date":"2021-05-20","kind":"grant","acquired":true,"shares":6667,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares vest on the first anniversary of the Grant Date, provided that the Option will in any case be fully vested on the date of Company's 2022 annual stockholder meeting, subject to the Reporting Person's Continuous Service (as defined in the 2020 Equity Incentive Plan (the \"Plan\")) through such vesting date and will vest in full upon a Change in Control (as defined in the Plan)."}],"balance_after":6667,"derivative":{"exercise_price":15.24,"expiration_date":"2031-05-19","underlying":"Common Stock","underlying_shares":6667},"source":{"system":"sec-edgar","filing":"0001209191-21-035152","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1683553/000120919121035152/doc4.xml","form_type":"4"}},{"id":2955663,"issuer":{"id":5953,"kind":"organization","name":"MYRIAD GENETICS INC","symbol":"MYGN"},"owners":[{"id":34781,"kind":"person","name":"SPIEGELMAN DANIEL K","position":1,"cik":"0001238403","reported_name":"SPIEGELMAN DANIEL K","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-12-07T22:27:07.000Z","date":"2020-12-04","kind":"grant","acquired":true,"shares":15889,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Consists of restricted stock units granted pursuant to the Company's 2017 Employee, Director and Consultant Equity Incentive Plan. Each restricted stock unit represents a contingent right to receive one share of the Company's common stock and vests on the anniversary of the date of grant."}],"balance_after":36451,"source":{"system":"sec-edgar","filing":"0001238403-20-000007","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/899923/000123840320000007/edgardoc.xml","form_type":"4"}},{"id":3132760,"issuer":{"id":5953,"kind":"organization","name":"MYRIAD GENETICS INC","symbol":"MYGN"},"owners":[{"id":34781,"kind":"person","name":"SPIEGELMAN DANIEL K","position":1,"cik":"0001238403","reported_name":"SPIEGELMAN DANIEL K","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-05-28T15:17:08.000Z","date":"2020-05-27","kind":"grant","acquired":true,"shares":20562,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Consists of restricted stock units granted pursuant to the Company's 2017 Employee, Director and Consultant Equity Incentive Plan. Each restricted stock unit represents a contingent right to receive one share of the Company's common stock and vests on the anniversary of the date of grant."}],"balance_after":20562,"source":{"system":"sec-edgar","filing":"0001238403-20-000005","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/899923/000123840320000005/edgardoc.xml","form_type":"4"}},{"id":3497528,"issuer":{"id":2404,"kind":"organization","name":"BIOMARIN PHARMACEUTICAL INC","symbol":"BMRN"},"owners":[{"id":34781,"kind":"person","name":"SPIEGELMAN DANIEL K","position":1,"cik":"0001238403","reported_name":"SPIEGELMAN DANIEL K","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Financial Officer"}}],"security":"Common Stock","published_at":"2019-06-07T22:51:03.000Z","date":"2019-04-30","kind":"grant","acquired":true,"shares":176,"price":68.782,"value":12105.632,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"Represents shares acquired by the reporting person on April 30, 2019, pursuant to the issuer's Employee Stock Purchase Plan."}],"balance_after":47686,"source":{"system":"sec-edgar","filing":"0001567619-19-013093","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1048477/000156761919013093/doc1.xml","form_type":"4"}},{"id":3565920,"issuer":{"id":2404,"kind":"organization","name":"BIOMARIN PHARMACEUTICAL INC","symbol":"BMRN"},"owners":[{"id":34781,"kind":"person","name":"SPIEGELMAN DANIEL K","position":1,"cik":"0001238403","reported_name":"SPIEGELMAN DANIEL K","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Financial Officer"}}],"security":"Common Stock","published_at":"2019-04-03T17:17:55.000Z","date":"2019-04-01","kind":"sale","acquired":false,"shares":13473,"price":89,"value":1199097.0,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"Trade made pursuant to a 10b5-1 plan executed on February 26, 2019."}],"balance_after":47510,"source":{"system":"sec-edgar","filing":"0001567619-19-008275","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1048477/000156761919008275/doc1.xml","form_type":"4"}},{"id":3574176,"issuer":{"id":2404,"kind":"organization","name":"BIOMARIN PHARMACEUTICAL INC","symbol":"BMRN"},"owners":[{"id":34781,"kind":"person","name":"SPIEGELMAN DANIEL K","position":1,"cik":"0001238403","reported_name":"SPIEGELMAN DANIEL K","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Financial Officer"}}],"security":"Common Stock","published_at":"2019-03-29T22:19:57.000Z","date":"2019-03-27","kind":"sale","acquired":false,"shares":100,"price":90,"value":9000.0,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"Trade made pursuant to a 10b5-1 plan executed on February 26, 2019."}],"balance_after":60983,"source":{"system":"sec-edgar","filing":"0001567619-19-007872","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1048477/000156761919007872/doc1.xml","form_type":"4"}},{"id":3578835,"issuer":{"id":2404,"kind":"organization","name":"BIOMARIN PHARMACEUTICAL INC","symbol":"BMRN"},"owners":[{"id":34781,"kind":"person","name":"SPIEGELMAN DANIEL K","position":1,"cik":"0001238403","reported_name":"SPIEGELMAN DANIEL K","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Financial Officer"}}],"security":"Common Stock","published_at":"2019-03-27T00:30:09.000Z","date":"2019-03-22","kind":"tax_withholding","acquired":false,"shares":3598,"price":88.05,"value":316803.9,"ownership":{"direct":true},"balance_after":61083,"source":{"system":"sec-edgar","filing":"0001567619-19-007684","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1048477/000156761919007684/doc1.xml","form_type":"4"}},{"id":3588344,"issuer":{"id":2404,"kind":"organization","name":"BIOMARIN PHARMACEUTICAL INC","symbol":"BMRN"},"owners":[{"id":34781,"kind":"person","name":"SPIEGELMAN DANIEL K","position":1,"cik":"0001238403","reported_name":"SPIEGELMAN DANIEL K","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Financial Officer"}}],"security":"Stock Option (Right to buy Common Stock)","published_at":"2019-03-20T00:43:33.000Z","date":"2019-03-15","kind":"grant","acquired":true,"shares":23450,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F2","text":"Option grant vests 12/48th on March 15, 2020 and 1/48th on the 15th day of each month thereafter."}],"balance_after":23450,"derivative":{"exercise_price":94.53,"exercise_date":"2020-03-15","expiration_date":"2029-03-14","underlying":"Common Stock","underlying_shares":23450},"source":{"system":"sec-edgar","filing":"0001567619-19-007257","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1048477/000156761919007257/doc1.xml","form_type":"4"}},{"id":3588343,"issuer":{"id":2404,"kind":"organization","name":"BIOMARIN PHARMACEUTICAL INC","symbol":"BMRN"},"owners":[{"id":34781,"kind":"person","name":"SPIEGELMAN DANIEL K","position":1,"cik":"0001238403","reported_name":"SPIEGELMAN DANIEL K","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Financial Officer"}}],"security":"Common Stock","published_at":"2019-03-20T00:43:33.000Z","date":"2019-03-15","kind":"grant","acquired":true,"shares":9370,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Restricted stock units granted on March 15, 2019. Price not applicable."}],"balance_after":64681,"source":{"system":"sec-edgar","filing":"0001567619-19-007257","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1048477/000156761919007257/doc1.xml","form_type":"4"}},{"id":3588342,"issuer":{"id":2404,"kind":"organization","name":"BIOMARIN PHARMACEUTICAL INC","symbol":"BMRN"},"owners":[{"id":34781,"kind":"person","name":"SPIEGELMAN DANIEL K","position":1,"cik":"0001238403","reported_name":"SPIEGELMAN DANIEL K","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Financial Officer"}}],"security":"Common Stock","published_at":"2019-03-20T00:43:33.000Z","date":"2019-03-15","kind":"tax_withholding","acquired":false,"shares":7227,"price":94.53,"value":683168.31,"ownership":{"direct":true},"balance_after":55311,"source":{"system":"sec-edgar","filing":"0001567619-19-007257","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1048477/000156761919007257/doc1.xml","form_type":"4"}},{"id":3614460,"issuer":{"id":2404,"kind":"organization","name":"BIOMARIN PHARMACEUTICAL INC","symbol":"BMRN"},"owners":[{"id":34781,"kind":"person","name":"SPIEGELMAN DANIEL K","position":1,"cik":"0001238403","reported_name":"SPIEGELMAN DANIEL K","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Financial Officer"}}],"security":"Common Stock","published_at":"2019-03-06T01:08:37.000Z","date":"2019-03-01","kind":"tax_withholding","acquired":false,"shares":912,"price":94.76,"value":86421.12,"ownership":{"direct":true},"balance_after":62538,"source":{"system":"sec-edgar","filing":"0001567619-19-006240","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1048477/000156761919006240/doc1.xml","form_type":"4"}},{"id":3614459,"issuer":{"id":2404,"kind":"organization","name":"BIOMARIN PHARMACEUTICAL INC","symbol":"BMRN"},"owners":[{"id":34781,"kind":"person","name":"SPIEGELMAN DANIEL K","position":1,"cik":"0001238403","reported_name":"SPIEGELMAN DANIEL K","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Financial Officer"}}],"security":"Common Stock","published_at":"2019-03-06T01:08:37.000Z","date":"2019-03-01","kind":"grant","acquired":true,"shares":12205,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"Transaction Date is the date that the Issuer's Board of Directors' Compensation Committee Chair certified that the reporting person earned the Restricted Stock Units (RSUs), which are convertible into shares of the Issuer's Common Stock on a 1:1 basis."},{"field":"shares","element":"transactionShares","label":"F2","text":"Represents the total number of RSUs earned pursuant to a calculation set forth in the performance-based RSU awards previously granted under the Issuer's 2017 Equity Incentive Plan based on the level of the Issuer's total adjusted net product revenues for the fiscal year ended December 31, 2018 as set forth in the Issuer's audited financial statements."},{"field":"shares","element":"transactionShares","label":"F3","text":"Although earned, the RSUs only vest according to the following schedule: 1/3 vests on each of March 15, 2019, 2020 and 2021, so long as the reporting person remains continuously employed with the Issuer through that date, subject to earlier vesting upon certain events."}],"balance_after":63450,"source":{"system":"sec-edgar","filing":"0001567619-19-006240","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1048477/000156761919006240/doc1.xml","form_type":"4"}},{"id":3723587,"issuer":{"id":2404,"kind":"organization","name":"BIOMARIN PHARMACEUTICAL INC","symbol":"BMRN"},"owners":[{"id":34781,"kind":"person","name":"SPIEGELMAN DANIEL K","position":1,"cik":"0001238403","reported_name":"SPIEGELMAN DANIEL K","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Financial Officer"}}],"security":"Common Stock","published_at":"2018-12-20T23:06:01.000Z","date":"2018-10-31","kind":"grant","acquired":true,"shares":175,"price":68.782,"value":12036.85,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"Represents shares acquired by the reporting person on October 31, 2018, pursuant to the issuer's Employee Stock Purchase Plan."}],"balance_after":51245,"source":{"system":"sec-edgar","filing":"0001567619-18-008459","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1048477/000156761918008459/doc1.xml","form_type":"4"}},{"id":3883371,"issuer":{"id":2404,"kind":"organization","name":"BIOMARIN PHARMACEUTICAL INC","symbol":"BMRN"},"owners":[{"id":34781,"kind":"person","name":"SPIEGELMAN DANIEL K","position":1,"cik":"0001238403","reported_name":"SPIEGELMAN DANIEL K","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Financial Officer"}}],"security":"Common Stock","published_at":"2018-06-27T00:31:30.000Z","date":"2018-06-22","kind":"sale","acquired":false,"shares":472,"price":99.01,"value":46732.72,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"Trade made pursuant to a 10b5-1 plan executed on August 15, 2017."}],"balance_after":51070,"source":{"system":"sec-edgar","filing":"0001140361-18-030011","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1048477/000114036118030011/doc1.xml","form_type":"4"}},{"id":3883370,"issuer":{"id":2404,"kind":"organization","name":"BIOMARIN PHARMACEUTICAL INC","symbol":"BMRN"},"owners":[{"id":34781,"kind":"person","name":"SPIEGELMAN DANIEL K","position":1,"cik":"0001238403","reported_name":"SPIEGELMAN DANIEL K","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Financial Officer"}}],"security":"Common Stock","published_at":"2018-06-27T00:31:30.000Z","date":"2018-06-22","kind":"sale","acquired":false,"shares":9528,"price":99,"value":943272.0,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"Trade made pursuant to a 10b5-1 plan executed on August 15, 2017."}],"balance_after":51542,"source":{"system":"sec-edgar","filing":"0001140361-18-030011","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1048477/000114036118030011/doc1.xml","form_type":"4"}},{"id":3903757,"issuer":{"id":2404,"kind":"organization","name":"BIOMARIN PHARMACEUTICAL INC","symbol":"BMRN"},"owners":[{"id":34781,"kind":"person","name":"SPIEGELMAN DANIEL K","position":1,"cik":"0001238403","reported_name":"SPIEGELMAN DANIEL K","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Financial Officer"}}],"security":"Common Stock","published_at":"2018-06-07T00:15:40.000Z","date":"2018-06-04","kind":"tax_withholding","acquired":false,"shares":1711,"price":92.07,"value":157531.77,"ownership":{"direct":true},"balance_after":61070,"source":{"system":"sec-edgar","filing":"0001140361-18-027605","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1048477/000114036118027605/doc1.xml","form_type":"4"}},{"id":3903756,"issuer":{"id":2404,"kind":"organization","name":"BIOMARIN PHARMACEUTICAL INC","symbol":"BMRN"},"owners":[{"id":34781,"kind":"person","name":"SPIEGELMAN DANIEL K","position":1,"cik":"0001238403","reported_name":"SPIEGELMAN DANIEL K","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Financial Officer"}}],"security":"Common Stock","published_at":"2018-06-07T00:15:40.000Z","date":"2018-04-30","kind":"grant","acquired":true,"shares":167,"price":68.782,"value":11486.594,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"Represents shares acquired by the reporting person on April 30, 2018, pursuant to the issuer's Employee Stock Purchase Plan."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Amount of securities beneficially owned has been adjusted from the reporting person's prior report to: a) add 86 shares reported as acquired in the Form 4 Amendment filed with the S.E.C. on 4/26/2018; and b) subtract 15 shares reported as disposed of in the Form 4 Amendment filed with the S.E.C. on 4/27/2018."}],"balance_after":62781,"source":{"system":"sec-edgar","filing":"0001140361-18-027605","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1048477/000114036118027605/doc1.xml","form_type":"4"}},{"id":3955188,"issuer":{"id":2404,"kind":"organization","name":"BIOMARIN PHARMACEUTICAL INC","symbol":"BMRN"},"owners":[{"id":34781,"kind":"person","name":"SPIEGELMAN DANIEL K","position":1,"cik":"0001238403","reported_name":"SPIEGELMAN DANIEL K","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Financial Officer"}}],"security":"Common Stock","published_at":"2018-04-27T23:32:08.000Z","date":"2018-03-22","kind":"tax_withholding","acquired":false,"shares":3598,"price":81.36,"value":292733.28,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This amendment is being filed solely to correct an administrative error in the original filing regarding the number of shares reported as forfeited."}],"balance_after":73587,"source":{"system":"sec-edgar","filing":"0001140361-18-020306","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1048477/000114036118020306/doc1.xml","form_type":"4/A","original_submission_date":"2018-03-26"}},{"id":3956339,"issuer":{"id":2404,"kind":"organization","name":"BIOMARIN PHARMACEUTICAL INC","symbol":"BMRN"},"owners":[{"id":34781,"kind":"person","name":"SPIEGELMAN DANIEL K","position":1,"cik":"0001238403","reported_name":"SPIEGELMAN DANIEL K","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Financial Officer"}}],"security":"Common Stock","published_at":"2018-04-27T01:04:09.000Z","date":"2018-02-26","kind":"grant","acquired":true,"shares":12615,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"Transaction Date is the date that the Issuer's Board of Directors' Compensation Committee Chair certified that the reporting person earned the Restricted Stock Units (RSUs), which are convertible into shares of the Issuer's Common Stock on a 1:1 basis."},{"field":"shares","element":"transactionShares","label":"F2","text":"Represents the total number of RSUs earned pursuant to a calculation set forth in the performance-based RSU awards previously granted under the Issuer's 2006 Share Incentive Plan based on the level of the Issuer's total adjusted net product revenues for the fiscal year ended December 31, 2017 as set forth in the Issuer's audited financial statements."},{"field":"shares","element":"transactionShares","label":"F3","text":"Although earned, the RSUs only vest according to the following schedule: 1/3 vests on each of March 22, 2018, 2019 and 2020, so long as the reporting person remains continuously employed with the Issuer through that date, subject to earlier vesting upon certain events."},{"field":"shares","element":"transactionShares","label":"F4","text":"This amendment is being filed solely to correct an administrative error in the original filing regarding the number of RSUs reported as earned."}],"balance_after":70215,"source":{"system":"sec-edgar","filing":"0001140361-18-019878","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1048477/000114036118019878/doc1.xml","form_type":"4/A","original_submission_date":"2018-02-28"}},{"id":3957325,"issuer":{"id":2404,"kind":"organization","name":"BIOMARIN PHARMACEUTICAL INC","symbol":"BMRN"},"owners":[{"id":34781,"kind":"person","name":"SPIEGELMAN DANIEL K","position":1,"cik":"0001238403","reported_name":"SPIEGELMAN DANIEL K","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Financial Officer"}}],"security":"Common Stock","published_at":"2018-04-26T00:37:59.000Z","date":"2018-04-23","kind":"sale","acquired":false,"shares":11059,"price":82.15,"value":908496.85,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"Trade made pursuant to a 10b5-1 plan executed on December 11, 2017."}],"balance_after":62543,"source":{"system":"sec-edgar","filing":"0001140361-18-019613","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1048477/000114036118019613/doc1.xml","form_type":"4"}},{"id":3983258,"issuer":{"id":2404,"kind":"organization","name":"BIOMARIN PHARMACEUTICAL INC","symbol":"BMRN"},"owners":[{"id":34781,"kind":"person","name":"SPIEGELMAN DANIEL K","position":1,"cik":"0001238403","reported_name":"SPIEGELMAN DANIEL K","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Financial Officer"}}],"security":"Common Stock","published_at":"2018-03-27T00:08:27.000Z","date":"2018-03-22","kind":"tax_withholding","acquired":false,"shares":3583,"price":81.36,"value":291512.88,"ownership":{"direct":true},"balance_after":73602,"source":{"system":"sec-edgar","filing":"0001140361-18-015081","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1048477/000114036118015081/doc1.xml","form_type":"4"}},{"id":3990178,"issuer":{"id":2404,"kind":"organization","name":"BIOMARIN PHARMACEUTICAL INC","symbol":"BMRN"},"owners":[{"id":34781,"kind":"person","name":"SPIEGELMAN DANIEL K","position":1,"cik":"0001238403","reported_name":"SPIEGELMAN DANIEL K","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Financial Officer"}}],"security":"Stock Option (Right to buy Common Stock)","published_at":"2018-03-20T01:45:25.000Z","date":"2018-03-15","kind":"grant","acquired":true,"shares":39900,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Option grant vests 12/48th on March 15, 2019 and 1/48th on the 15th day of each month thereafter."}],"balance_after":39900,"derivative":{"exercise_price":83.57,"exercise_date":"2018-03-15","expiration_date":"2028-03-14","underlying":"Common Stock","underlying_shares":39900},"source":{"system":"sec-edgar","filing":"0001140361-18-014184","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1048477/000114036118014184/doc1.xml","form_type":"4"}},{"id":3990177,"issuer":{"id":2404,"kind":"organization","name":"BIOMARIN PHARMACEUTICAL INC","symbol":"BMRN"},"owners":[{"id":34781,"kind":"person","name":"SPIEGELMAN DANIEL K","position":1,"cik":"0001238403","reported_name":"SPIEGELMAN DANIEL K","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Financial Officer"}}],"security":"Common Stock","published_at":"2018-03-20T01:45:25.000Z","date":"2018-03-15","kind":"grant","acquired":true,"shares":12480,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Restricted stock units granted on March 15, 2018.  Price not applicable."}],"balance_after":77185,"source":{"system":"sec-edgar","filing":"0001140361-18-014184","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1048477/000114036118014184/doc1.xml","form_type":"4"}},{"id":3990176,"issuer":{"id":2404,"kind":"organization","name":"BIOMARIN PHARMACEUTICAL INC","symbol":"BMRN"},"owners":[{"id":34781,"kind":"person","name":"SPIEGELMAN DANIEL K","position":1,"cik":"0001238403","reported_name":"SPIEGELMAN DANIEL K","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Financial Officer"}}],"security":"Common Stock","published_at":"2018-03-20T01:45:25.000Z","date":"2018-03-15","kind":"tax_withholding","acquired":false,"shares":3815,"price":83.57,"value":318819.55,"ownership":{"direct":true},"balance_after":64705,"source":{"system":"sec-edgar","filing":"0001140361-18-014184","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1048477/000114036118014184/doc1.xml","form_type":"4"}},{"id":3998153,"issuer":{"id":168341,"kind":"organization","name":"Cascadian Therapeutics, Inc.","symbol":"CASC"},"owners":[{"id":34781,"kind":"person","name":"SPIEGELMAN DANIEL K","position":1,"cik":"0001238403","reported_name":"SPIEGELMAN DANIEL K","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2018-03-13T18:07:15.000Z","date":"2018-03-09","kind":"disposition_to_issuer","acquired":false,"shares":13927,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Pursuant to the Merger Agreement, the restricted stock units were cancelled in exchange for a cash payment of $139,270, which is the product of the total number of shares subject to such restricted stock unit grant multiplied by the Offer Price."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the Merger Agreement, the restricted stock units were cancelled in exchange for a cash payment of $139,270, which is the product of the total number of shares subject to such restricted stock unit grant multiplied by the Offer Price."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The restricted stock units were granted on June 9, 2017 and vest on the one-year anniversary of the grant date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The restricted stock units expire upon the earlier of the settlement of the units and the unitholder's termination of service."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":13927},"source":{"system":"sec-edgar","filing":"0000899243-18-007301","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1412067/000089924318007301/doc4.xml","form_type":"4"}},{"id":3998152,"issuer":{"id":168341,"kind":"organization","name":"Cascadian Therapeutics, Inc.","symbol":"CASC"},"owners":[{"id":34781,"kind":"person","name":"SPIEGELMAN DANIEL K","position":1,"cik":"0001238403","reported_name":"SPIEGELMAN DANIEL K","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-03-13T18:07:15.000Z","date":"2018-03-09","kind":"other","acquired":false,"shares":21006,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Shares of Common Stock tendered in the tender offer launched by Valley Acquisition Sub, Inc. on February 8, 2018 pursuant to that certain Agreement and Plan of Merger, dated January 30, 2018, among Seattle Genetics, Inc., Valley Acquisition Sub, Inc., and Cascadian Therapeutics, Inc. (the \"Merger Agreement\"), to acquire all of the outstanding shares of common stock of Cascadian Therapeutics, Inc., par value $0.0001 per share, at a purchase price of $10.00 per share (\"Offer Price\"), net to the seller in cash, without interest and less any required withholding taxes."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000899243-18-007301","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1412067/000089924318007301/doc4.xml","form_type":"4"}},{"id":4011925,"issuer":{"id":2404,"kind":"organization","name":"BIOMARIN PHARMACEUTICAL INC","symbol":"BMRN"},"owners":[{"id":34781,"kind":"person","name":"SPIEGELMAN DANIEL K","position":1,"cik":"0001238403","reported_name":"SPIEGELMAN DANIEL K","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Financial Officer"}}],"security":"Common Stock","published_at":"2018-03-07T01:48:46.000Z","date":"2018-03-02","kind":"tax_withholding","acquired":false,"shares":1609,"price":79.86,"value":128494.74,"ownership":{"direct":true},"balance_after":68520,"source":{"system":"sec-edgar","filing":"0001140361-18-012370","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1048477/000114036118012370/doc1.xml","form_type":"4"}},{"id":4028096,"issuer":{"id":2404,"kind":"organization","name":"BIOMARIN PHARMACEUTICAL INC","symbol":"BMRN"},"owners":[{"id":34781,"kind":"person","name":"SPIEGELMAN DANIEL K","position":1,"cik":"0001238403","reported_name":"SPIEGELMAN DANIEL K","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Financial Officer"}}],"security":"Common Stock","published_at":"2018-03-01T01:57:55.000Z","date":"2018-02-26","kind":"grant","acquired":true,"shares":12529,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"Transaction Date is the date that the Issuer's Board of Directors' Compensation Committee Chair certified that the reporting person earned the Restricted Stock Units (RSUs), which are convertible into shares of the Issuer's Common Stock on a 1:1 basis."},{"field":"shares","element":"transactionShares","label":"F2","text":"Represents the total number of RSUs earned pursuant to a calculation set forth in the performance-based RSU awards previously granted under the Issuer's 2006 Share Incentive Plan based on the level of the Issuer's total adjusted net product revenues for the fiscal year ended December 31, 2017 as set forth in the Issuer's audited financial statements."},{"field":"shares","element":"transactionShares","label":"F3","text":"Although earned, the RSUs only vest according to the following schedule: 1/3 vests on each of March 22, 2018, 2019 and 2020, so long as the reporting person remains continuously employed with the Issuer through that date, subject to earlier vesting upon certain events."}],"balance_after":70129,"source":{"system":"sec-edgar","filing":"0001140361-18-011000","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1048477/000114036118011000/doc1.xml","form_type":"4"}},{"id":4059755,"issuer":{"id":2404,"kind":"organization","name":"BIOMARIN PHARMACEUTICAL INC","symbol":"BMRN"},"owners":[{"id":34781,"kind":"person","name":"SPIEGELMAN DANIEL K","position":1,"cik":"0001238403","reported_name":"SPIEGELMAN DANIEL K","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Financial Officer"}}],"security":"Common Stock","published_at":"2018-02-15T01:23:59.000Z","date":"2017-10-31","kind":"grant","acquired":true,"shares":162,"price":69.777,"value":11303.874,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"Represents shares acquired by the reporting person on October 31, 2017, pursuant to the issuer's Employee Stock Purchase Plan."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Amount of securities beneficially owned has been updated from the reporting person's prior report to:  a) include 34,078 shares reported in the Form 4 Amendment filed with the S.E.C. on 10/13/2017; and b) include 57 shares inadvertently excluded in prior reports based on a reconciliation with the Company's records."}],"balance_after":57600,"source":{"system":"sec-edgar","filing":"0001140361-18-008551","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1048477/000114036118008551/doc1.xml","form_type":"5"}},{"id":4186892,"issuer":{"id":2404,"kind":"organization","name":"BIOMARIN PHARMACEUTICAL INC","symbol":"BMRN"},"owners":[{"id":34781,"kind":"person","name":"SPIEGELMAN DANIEL K","position":1,"cik":"0001238403","reported_name":"SPIEGELMAN DANIEL K","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Financial Officer"}}],"security":"Stock Option (Right to buy Common Stock)","published_at":"2017-10-14T00:43:32.000Z","date":"2015-05-27","kind":"exercise","acquired":false,"shares":34078,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"On May 28, 2015, the reporting person filed a Form 4 which inadvertently failed to report this option exercise."},{"field":"date","element":"transactionDate","label":"F2","text":"Trade made pursuant to a 10b5-1 plan executed on March 11, 2015."}],"balance_after":35552,"derivative":{"exercise_price":67.81,"exercise_date":"2013-11-15","expiration_date":"2023-05-14","underlying":"Common Stock","underlying_shares":34078},"source":{"system":"sec-edgar","filing":"0001140361-17-038689","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1048477/000114036117038689/doc1.xml","form_type":"4/A","original_submission_date":"2015-05-28"}},{"id":4186891,"issuer":{"id":2404,"kind":"organization","name":"BIOMARIN PHARMACEUTICAL INC","symbol":"BMRN"},"owners":[{"id":34781,"kind":"person","name":"SPIEGELMAN DANIEL K","position":1,"cik":"0001238403","reported_name":"SPIEGELMAN DANIEL K","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Financial Officer"}}],"security":"Common Stock","published_at":"2017-10-14T00:43:32.000Z","date":"2015-05-27","kind":"sale","acquired":false,"shares":34078,"price":130,"value":4430140.0,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F3","text":"On May 28, 2015, the reporting person filed a Form 4 which inadvertently reported an incorrect transaction date and deemed execution date.  This amendment corrects such date."},{"field":"date","element":"transactionDate","label":"F2","text":"Trade made pursuant to a 10b5-1 plan executed on March 11, 2015."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"All shares sold at same price."}],"balance_after":75585,"source":{"system":"sec-edgar","filing":"0001140361-17-038689","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1048477/000114036117038689/doc1.xml","form_type":"4/A","original_submission_date":"2015-05-28"}},{"id":4186890,"issuer":{"id":2404,"kind":"organization","name":"BIOMARIN PHARMACEUTICAL INC","symbol":"BMRN"},"owners":[{"id":34781,"kind":"person","name":"SPIEGELMAN DANIEL K","position":1,"cik":"0001238403","reported_name":"SPIEGELMAN DANIEL K","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Financial Officer"}}],"security":"Common Stock","published_at":"2017-10-14T00:43:32.000Z","date":"2015-05-27","kind":"exercise","acquired":true,"shares":34078,"price":67.81,"value":2310829.18,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"On May 28, 2015, the reporting person filed a Form 4 which inadvertently failed to report this option exercise."},{"field":"date","element":"transactionDate","label":"F2","text":"Trade made pursuant to a 10b5-1 plan executed on March 11, 2015."}],"balance_after":109663,"source":{"system":"sec-edgar","filing":"0001140361-17-038689","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1048477/000114036117038689/doc1.xml","form_type":"4/A","original_submission_date":"2015-05-28"}},{"id":4201480,"issuer":{"id":168341,"kind":"organization","name":"Cascadian Therapeutics, Inc.","symbol":"CASC"},"owners":[{"id":34781,"kind":"person","name":"SPIEGELMAN DANIEL K","position":1,"cik":"0001238403","reported_name":"SPIEGELMAN DANIEL K","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Share Unit (RSU)","published_at":"2017-09-26T17:22:27.000Z","date":"2017-09-24","kind":"exercise","acquired":false,"shares":2375,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Approximately 75% of each RSU represents a contingent right to receive approximately 0.75 share of the issuer's Common Stock upon vesting and approximately 25% represents a contingent right to receive cash upon vesting, which cash will be used to facilitate such holder's satisfaction of U.S. federal income tax obligations in connection with the vesting of the RSUs."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The RSU was 100% vested on September 24, 2017."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The RSU was 100% vested on September 24, 2017."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":2375},"source":{"system":"sec-edgar","filing":"0001209191-17-054020","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1412067/000120919117054020/doc4.xml","form_type":"4"}},{"id":4201479,"issuer":{"id":168341,"kind":"organization","name":"Cascadian Therapeutics, Inc.","symbol":"CASC"},"owners":[{"id":34781,"kind":"person","name":"SPIEGELMAN DANIEL K","position":1,"cik":"0001238403","reported_name":"SPIEGELMAN DANIEL K","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2017-09-26T17:22:27.000Z","date":"2017-09-24","kind":"tax_withholding","acquired":false,"shares":594,"price":3.94,"value":2340.36,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"594 shares of the restricted share unit (\"RSU\") grant, which represent approximately 25% of the shares underlying the RSU grant that vested on September 24, 2017, were not issued to the reporting holder; instead the reporting holder received an amount in cash from the issuer equal to the value of such shares based on the closing price of the issuer's Common Stock on September 22, 2017, the most recent date prior to the vesting date on which the issuer's Common Stock was traded, to facilitate such holder's satisfaction of U.S. federal income tax obligations in connection with the vesting of the RSUs, which transaction does not represent a sale by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"594 shares of the restricted share unit (\"RSU\") grant, which represent approximately 25% of the shares underlying the RSU grant that vested on September 24, 2017, were not issued to the reporting holder; instead the reporting holder received an amount in cash from the issuer equal to the value of such shares based on the closing price of the issuer's Common Stock on September 22, 2017, the most recent date prior to the vesting date on which the issuer's Common Stock was traded, to facilitate such holder's satisfaction of U.S. federal income tax obligations in connection with the vesting of the RSUs, which transaction does not represent a sale by the reporting person."}],"balance_after":21006,"source":{"system":"sec-edgar","filing":"0001209191-17-054020","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1412067/000120919117054020/doc4.xml","form_type":"4"}},{"id":4201478,"issuer":{"id":168341,"kind":"organization","name":"Cascadian Therapeutics, Inc.","symbol":"CASC"},"owners":[{"id":34781,"kind":"person","name":"SPIEGELMAN DANIEL K","position":1,"cik":"0001238403","reported_name":"SPIEGELMAN DANIEL K","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2017-09-26T17:22:27.000Z","date":"2017-09-24","kind":"exercise","acquired":true,"shares":2375,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":21600,"source":{"system":"sec-edgar","filing":"0001209191-17-054020","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1412067/000120919117054020/doc4.xml","form_type":"4"}},{"id":4271643,"issuer":{"id":168341,"kind":"organization","name":"Cascadian Therapeutics, Inc.","symbol":"CASC"},"owners":[{"id":34781,"kind":"person","name":"SPIEGELMAN DANIEL K","position":1,"cik":"0001238403","reported_name":"SPIEGELMAN DANIEL K","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Share Unit (RSU)","published_at":"2017-06-27T17:41:54.000Z","date":"2017-06-24","kind":"exercise","acquired":false,"shares":9058,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Approximately 75% of each RSU represents a contingent right to receive approximately 0.75 share of the issuer's Common Stock upon vesting and approximately 25% represents a contingent right to receive cash upon vesting, which cash will be used to facilitate such holder's satisfaction of U.S. federal income tax obligations in connection with the vesting of the RSUs."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The RSU was 100% vested on June 24, 2017."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The RSU was 100% vested on June 24, 2017."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":9058},"source":{"system":"sec-edgar","filing":"0001209191-17-042008","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1412067/000120919117042008/doc4.xml","form_type":"4"}},{"id":4271642,"issuer":{"id":168341,"kind":"organization","name":"Cascadian Therapeutics, Inc.","symbol":"CASC"},"owners":[{"id":34781,"kind":"person","name":"SPIEGELMAN DANIEL K","position":1,"cik":"0001238403","reported_name":"SPIEGELMAN DANIEL K","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2017-06-27T17:41:54.000Z","date":"2017-06-24","kind":"tax_withholding","acquired":false,"shares":2265,"price":3.78,"value":8561.7,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"2,265 shares of the restricted share unit (\"RSU\") grant, which represent approximately 25% of the shares underlying the RSU grant that vested on June 24, 2017, were not issued to the reporting holder; instead the reporting holder received an amount in cash from the issuer equal to the value of such shares based on the closing price of the issuer's Common Stock on June 23, 2017, the most recent date prior to the vesting date on which the issuer's Common Stock was traded, to facilitate such holder's satisfaction of U.S. federal income tax obligations in connection with the vesting of the RSUs, which transaction does not represent a sale by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"2,265 shares of the restricted share unit (\"RSU\") grant, which represent approximately 25% of the shares underlying the RSU grant that vested on June 24, 2017, were not issued to the reporting holder; instead the reporting holder received an amount in cash from the issuer equal to the value of such shares based on the closing price of the issuer's Common Stock on June 23, 2017, the most recent date prior to the vesting date on which the issuer's Common Stock was traded, to facilitate such holder's satisfaction of U.S. federal income tax obligations in connection with the vesting of the RSUs, which transaction does not represent a sale by the reporting person."}],"balance_after":19225,"source":{"system":"sec-edgar","filing":"0001209191-17-042008","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1412067/000120919117042008/doc4.xml","form_type":"4"}},{"id":4271641,"issuer":{"id":168341,"kind":"organization","name":"Cascadian Therapeutics, Inc.","symbol":"CASC"},"owners":[{"id":34781,"kind":"person","name":"SPIEGELMAN DANIEL K","position":1,"cik":"0001238403","reported_name":"SPIEGELMAN DANIEL K","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2017-06-27T17:41:54.000Z","date":"2017-06-24","kind":"exercise","acquired":true,"shares":9058,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":21490,"source":{"system":"sec-edgar","filing":"0001209191-17-042008","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1412067/000120919117042008/doc4.xml","form_type":"4"}},{"id":4283579,"issuer":{"id":168341,"kind":"organization","name":"Cascadian Therapeutics, Inc.","symbol":"CASC"},"owners":[{"id":34781,"kind":"person","name":"SPIEGELMAN DANIEL K","position":1,"cik":"0001238403","reported_name":"SPIEGELMAN DANIEL K","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Share Unit (RSU)","published_at":"2017-06-13T16:42:19.000Z","date":"2017-06-12","kind":"exercise","acquired":false,"shares":2148,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Approximately 75% of each RSU represents a contingent right to receive approximately 0.75 share of the issuer's Common Stock upon vesting and approximately 25% represents a contingent right to receive cash upon vesting, which cash will be used to facilitate such holder's satisfaction of U.S. federal income tax obligations in connection with the vesting of the RSUs."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The RSU was 100% vested on June 12, 2017."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The RSU was 100% vested on June 12, 2017."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":2148},"source":{"system":"sec-edgar","filing":"0001209191-17-039503","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1412067/000120919117039503/doc4.xml","form_type":"4"}},{"id":4283578,"issuer":{"id":168341,"kind":"organization","name":"Cascadian Therapeutics, Inc.","symbol":"CASC"},"owners":[{"id":34781,"kind":"person","name":"SPIEGELMAN DANIEL K","position":1,"cik":"0001238403","reported_name":"SPIEGELMAN DANIEL K","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Share Unit (RSU)","published_at":"2017-06-13T16:42:19.000Z","date":"2017-06-09","kind":"grant","acquired":true,"shares":13927,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Approximately 75% of each RSU represents a contingent right to receive approximately 0.75 share of the issuer's Common Stock upon vesting and approximately 25% represents a contingent right to receive cash upon vesting, which cash will be used to facilitate such holder's satisfaction of U.S. federal income tax obligations in connection with the vesting of the RSUs."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"100% vests on the one-year anniversary of the Transaction Date, subject to acceleration under certain circumstances."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"100% vests on the one-year anniversary of the Transaction Date, subject to acceleration under certain circumstances."}],"balance_after":13927,"derivative":{"underlying":"Common Stock","underlying_shares":13927},"source":{"system":"sec-edgar","filing":"0001209191-17-039503","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1412067/000120919117039503/doc4.xml","form_type":"4"}},{"id":4283577,"issuer":{"id":168341,"kind":"organization","name":"Cascadian Therapeutics, Inc.","symbol":"CASC"},"owners":[{"id":34781,"kind":"person","name":"SPIEGELMAN DANIEL K","position":1,"cik":"0001238403","reported_name":"SPIEGELMAN DANIEL K","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2017-06-13T16:42:19.000Z","date":"2017-06-12","kind":"tax_withholding","acquired":false,"shares":537,"price":3.34,"value":1793.58,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"537 shares of the restricted share unit (\"RSU\") grant, which represent approximately 25% of the shares underlying the RSU grant that vested on June 12, 2017, were not issued to the reporting holder; instead the reporting holder received an amount in cash from the issuer equal to the value of such shares based on the closing price of the issuer's Common Stock on June 12, 2017 to facilitate such holder's satisfaction of U.S. federal income tax obligations in connection with the vesting of the RSUs, which transaction does not represent a sale by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"537 shares of the restricted share unit (\"RSU\") grant, which represent approximately 25% of the shares underlying the RSU grant that vested on June 12, 2017, were not issued to the reporting holder; instead the reporting holder received an amount in cash from the issuer equal to the value of such shares based on the closing price of the issuer's Common Stock on June 12, 2017 to facilitate such holder's satisfaction of U.S. federal income tax obligations in connection with the vesting of the RSUs, which transaction does not represent a sale by the reporting person."}],"balance_after":12432,"source":{"system":"sec-edgar","filing":"0001209191-17-039503","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1412067/000120919117039503/doc4.xml","form_type":"4"}},{"id":4283576,"issuer":{"id":168341,"kind":"organization","name":"Cascadian Therapeutics, Inc.","symbol":"CASC"},"owners":[{"id":34781,"kind":"person","name":"SPIEGELMAN DANIEL K","position":1,"cik":"0001238403","reported_name":"SPIEGELMAN DANIEL K","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2017-06-13T16:42:19.000Z","date":"2017-06-12","kind":"exercise","acquired":true,"shares":2148,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":12969,"source":{"system":"sec-edgar","filing":"0001209191-17-039503","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1412067/000120919117039503/doc4.xml","form_type":"4"}},{"id":4291533,"issuer":{"id":2404,"kind":"organization","name":"BIOMARIN PHARMACEUTICAL INC","symbol":"BMRN"},"owners":[{"id":34781,"kind":"person","name":"SPIEGELMAN DANIEL K","position":1,"cik":"0001238403","reported_name":"SPIEGELMAN DANIEL K","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Financial Officer"}}],"security":"Common Stock","published_at":"2017-06-07T01:07:20.000Z","date":"2017-06-02","kind":"tax_withholding","acquired":false,"shares":1801,"price":90.72,"value":163386.72,"ownership":{"direct":true},"balance_after":23303,"source":{"system":"sec-edgar","filing":"0001140361-17-024250","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1048477/000114036117024250/doc1.xml","form_type":"4"}},{"id":4316295,"issuer":{"id":2404,"kind":"organization","name":"BIOMARIN PHARMACEUTICAL INC","symbol":"BMRN"},"owners":[{"id":34781,"kind":"person","name":"SPIEGELMAN DANIEL K","position":1,"cik":"0001238403","reported_name":"SPIEGELMAN DANIEL K","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Financial Officer"}}],"security":"Common Stock","published_at":"2017-05-17T22:50:37.000Z","date":"2017-05-15","kind":"tax_withholding","acquired":false,"shares":1722,"price":91.5,"value":157563.0,"ownership":{"direct":true},"balance_after":25104,"source":{"system":"sec-edgar","filing":"0001140361-17-021241","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1048477/000114036117021241/doc1.xml","form_type":"4"}},{"id":4316294,"issuer":{"id":2404,"kind":"organization","name":"BIOMARIN PHARMACEUTICAL INC","symbol":"BMRN"},"owners":[{"id":34781,"kind":"person","name":"SPIEGELMAN DANIEL K","position":1,"cik":"0001238403","reported_name":"SPIEGELMAN DANIEL K","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Financial Officer"}}],"security":"Common Stock","published_at":"2017-05-17T22:50:37.000Z","date":"2017-04-28","kind":"grant","acquired":true,"shares":155,"price":70.304,"value":10897.12,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"Represents shares acquired by the reporting person pursuant to issuer's Employee Stock Purchase Plan."}],"balance_after":26826,"source":{"system":"sec-edgar","filing":"0001140361-17-021241","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1048477/000114036117021241/doc1.xml","form_type":"4"}},{"id":4372776,"issuer":{"id":2404,"kind":"organization","name":"BIOMARIN PHARMACEUTICAL INC","symbol":"BMRN"},"owners":[{"id":34781,"kind":"person","name":"SPIEGELMAN DANIEL K","position":1,"cik":"0001238403","reported_name":"SPIEGELMAN DANIEL K","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Financial Officer"}}],"security":"Stock Option (Right to buy Common Stock)","published_at":"2017-03-24T22:41:37.000Z","date":"2017-03-22","kind":"grant","acquired":true,"shares":39480,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Option grant vests 12/48th on March 22, 2018 and 1/48th on the 22nd day of each month thereafter."}],"balance_after":39480,"derivative":{"exercise_price":87.42,"exercise_date":"2018-03-22","expiration_date":"2027-03-21","underlying":"Common Stock","underlying_shares":39480},"source":{"system":"sec-edgar","filing":"0001140361-17-013315","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1048477/000114036117013315/doc1.xml","form_type":"4"}},{"id":4372775,"issuer":{"id":2404,"kind":"organization","name":"BIOMARIN PHARMACEUTICAL INC","symbol":"BMRN"},"owners":[{"id":34781,"kind":"person","name":"SPIEGELMAN DANIEL K","position":1,"cik":"0001238403","reported_name":"SPIEGELMAN DANIEL K","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Financial Officer"}}],"security":"Common Stock","published_at":"2017-03-24T22:41:37.000Z","date":"2017-03-22","kind":"grant","acquired":true,"shares":12200,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Restricted stock units granted on March 22, 2017.  Price not applicable."}],"balance_after":26671,"source":{"system":"sec-edgar","filing":"0001140361-17-013315","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1048477/000114036117013315/doc1.xml","form_type":"4"}},{"id":4380468,"issuer":{"id":2404,"kind":"organization","name":"BIOMARIN PHARMACEUTICAL INC","symbol":"BMRN"},"owners":[{"id":34781,"kind":"person","name":"SPIEGELMAN DANIEL K","position":1,"cik":"0001238403","reported_name":"SPIEGELMAN DANIEL K","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Financial Officer"}}],"security":"Common Stock","published_at":"2017-03-17T22:30:07.000Z","date":"2017-03-16","kind":"sale","acquired":false,"shares":1989,"price":91.96,"value":182908.44,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"Trade made pursuant to a 10b5-1 plan executed on November 16, 2016."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"All shares were sold at the same price."}],"balance_after":14471,"source":{"system":"sec-edgar","filing":"0001140361-17-012643","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1048477/000114036117012643/doc1.xml","form_type":"4"}},{"id":4380467,"issuer":{"id":2404,"kind":"organization","name":"BIOMARIN PHARMACEUTICAL INC","symbol":"BMRN"},"owners":[{"id":34781,"kind":"person","name":"SPIEGELMAN DANIEL K","position":1,"cik":"0001238403","reported_name":"SPIEGELMAN DANIEL K","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Financial Officer"}}],"security":"Common Stock","published_at":"2017-03-17T22:30:07.000Z","date":"2017-03-15","kind":"tax_withholding","acquired":false,"shares":4301,"price":92.5,"value":397842.5,"ownership":{"direct":true},"balance_after":16460,"source":{"system":"sec-edgar","filing":"0001140361-17-012643","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1048477/000114036117012643/doc1.xml","form_type":"4"}},{"id":4395475,"issuer":{"id":2404,"kind":"organization","name":"BIOMARIN PHARMACEUTICAL INC","symbol":"BMRN"},"owners":[{"id":34781,"kind":"person","name":"SPIEGELMAN DANIEL K","position":1,"cik":"0001238403","reported_name":"SPIEGELMAN DANIEL K","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Financial Officer"}}],"security":"Common Stock","published_at":"2017-03-09T00:28:27.000Z","date":"2017-03-06","kind":"sale","acquired":false,"shares":2303,"price":93.32,"value":214915.96,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"Trade made pursuant to a 10b5-1 plan executed on November 16, 2016."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"All shares were sold at the same price."}],"balance_after":20761,"source":{"system":"sec-edgar","filing":"0001140361-17-011079","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1048477/000114036117011079/doc1.xml","form_type":"4"}},{"id":4398285,"issuer":{"id":2404,"kind":"organization","name":"BIOMARIN PHARMACEUTICAL INC","symbol":"BMRN"},"owners":[{"id":34781,"kind":"person","name":"SPIEGELMAN DANIEL K","position":1,"cik":"0001238403","reported_name":"SPIEGELMAN DANIEL K","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Financial Officer"}}],"security":"Common Stock","published_at":"2017-03-07T23:38:53.000Z","date":"2017-03-03","kind":"tax_withholding","acquired":false,"shares":2283,"price":93.95,"value":214487.85,"ownership":{"direct":true},"balance_after":23064,"source":{"system":"sec-edgar","filing":"0001140361-17-010935","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1048477/000114036117010935/doc1.xml","form_type":"4"}},{"id":4410438,"issuer":{"id":2404,"kind":"organization","name":"BIOMARIN PHARMACEUTICAL INC","symbol":"BMRN"},"owners":[{"id":34781,"kind":"person","name":"SPIEGELMAN DANIEL K","position":1,"cik":"0001238403","reported_name":"SPIEGELMAN DANIEL K","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Financial Officer"}}],"security":"Stock Option (right to buy) Common Stock","published_at":"2017-03-02T23:20:13.000Z","date":"2017-02-28","kind":"exercise","acquired":false,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"Transaction made pursuant to a 10b5-1 trading plan executed on November 16, 2016."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Original option grant vests 6/48ths on December 4, 2014, and 1/48th on the 4th day of every month thereafter."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"Reflects the number of stock options that remain outstanding from this specific stock grant following the reported transaction."}],"balance_after":21700,"derivative":{"exercise_price":63.1,"exercise_date":"2014-12-04","expiration_date":"2024-06-03","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0001140361-17-010370","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1048477/000114036117010370/doc1.xml","form_type":"4"}},{"id":4410437,"issuer":{"id":2404,"kind":"organization","name":"BIOMARIN PHARMACEUTICAL INC","symbol":"BMRN"},"owners":[{"id":34781,"kind":"person","name":"SPIEGELMAN DANIEL K","position":1,"cik":"0001238403","reported_name":"SPIEGELMAN DANIEL K","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Financial Officer"}}],"security":"Common Stock","published_at":"2017-03-02T23:20:13.000Z","date":"2017-03-01","kind":"sale","acquired":false,"shares":5000,"price":94.5,"value":472500.0,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"Transaction made pursuant to a 10b5-1 trading plan executed on November 16, 2016."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"All shares were sold at the same price."}],"balance_after":25347,"source":{"system":"sec-edgar","filing":"0001140361-17-010370","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1048477/000114036117010370/doc1.xml","form_type":"4"}},{"id":4410436,"issuer":{"id":2404,"kind":"organization","name":"BIOMARIN PHARMACEUTICAL INC","symbol":"BMRN"},"owners":[{"id":34781,"kind":"person","name":"SPIEGELMAN DANIEL K","position":1,"cik":"0001238403","reported_name":"SPIEGELMAN DANIEL K","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Financial Officer"}}],"security":"Common Stock","published_at":"2017-03-02T23:20:13.000Z","date":"2017-02-28","kind":"sale","acquired":false,"shares":30000,"price":94,"value":2820000.0,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"Transaction made pursuant to a 10b5-1 trading plan executed on November 16, 2016."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"All shares were sold at the same price."}],"balance_after":30347,"source":{"system":"sec-edgar","filing":"0001140361-17-010370","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1048477/000114036117010370/doc1.xml","form_type":"4"}},{"id":4410435,"issuer":{"id":2404,"kind":"organization","name":"BIOMARIN PHARMACEUTICAL INC","symbol":"BMRN"},"owners":[{"id":34781,"kind":"person","name":"SPIEGELMAN DANIEL K","position":1,"cik":"0001238403","reported_name":"SPIEGELMAN DANIEL K","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Financial Officer"}}],"security":"Common Stock","published_at":"2017-03-02T23:20:13.000Z","date":"2017-02-28","kind":"exercise","acquired":true,"shares":30000,"price":63.1,"value":1893000.0,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"Transaction made pursuant to a 10b5-1 trading plan executed on November 16, 2016."}],"balance_after":60347,"source":{"system":"sec-edgar","filing":"0001140361-17-010370","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1048477/000114036117010370/doc1.xml","form_type":"4"}},{"id":4418464,"issuer":{"id":2404,"kind":"organization","name":"BIOMARIN PHARMACEUTICAL INC","symbol":"BMRN"},"owners":[{"id":34781,"kind":"person","name":"SPIEGELMAN DANIEL K","position":1,"cik":"0001238403","reported_name":"SPIEGELMAN DANIEL K","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Financial Officer"}}],"security":"Common Stock","published_at":"2017-02-28T21:51:05.000Z","date":"2017-02-24","kind":"grant","acquired":true,"shares":12247,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"Transaction Date is the date that the Issuer's Board of Directors' Compensation Committee Chair certified that the reporting person earned the Restricted Stock Units (RSUs), which are convertible into shares of the Issuer's Common Stock on a 1:1 basis."},{"field":"shares","element":"transactionShares","label":"F2","text":"Represents the total number of RSUs earned pursuant to a calculation based on the level of the Issuer's total adjusted revenues for the fiscal year ended December 31, 2016, as certified by its audited financials, set forth in the performance-based RSU awards previously granted under the Issuer's 2006 Share Incentive Plan."},{"field":"shares","element":"transactionShares","label":"F3","text":"Although earned, the RSUs only vest according to the following schedule: 1/3 vests on each of March 15, 2017, 2018 and 2019, so long as the reporting person remains continuously employed with the Issuer through that date, subject to earlier vesting upon certain corporate events."}],"balance_after":30347,"source":{"system":"sec-edgar","filing":"0001140361-17-009697","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1048477/000114036117009697/doc1.xml","form_type":"4"}},{"id":4457147,"issuer":{"id":168341,"kind":"organization","name":"Cascadian Therapeutics, Inc.","symbol":"CASC"},"owners":[{"id":34781,"kind":"person","name":"SPIEGELMAN DANIEL K","position":1,"cik":"0001238403","reported_name":"SPIEGELMAN DANIEL K","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Share Unit (RSU)","published_at":"2017-02-10T16:42:37.000Z","date":"2016-06-06","kind":"exercise","acquired":false,"shares":2723,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"Approximately 75% of each RSU represents a contingent right to receive approximately 0.75 share of the issuer's Common Stock upon vesting and approximately 25% represents a contingent right to receive cash upon vesting, which cash will be used to facilitate such holder's satisfaction of U.S. federal income tax obligations in connection with the vesting of the RSUs."},{"field":"shares","element":"transactionShares","label":"F1","text":"Effective as of November 29, 2016, the issuer effected a 6-for-1 reverse split of its common stock.  The number of shares above reflects the reverse stock split."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The RSU was 100% vested on June 6, 2016."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"The RSU was 100% vested on June 6, 2016."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":2723},"source":{"system":"sec-edgar","filing":"0001209191-17-009572","document":"doc5.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1412067/000120919117009572/doc5.xml","form_type":"5"}},{"id":4457146,"issuer":{"id":168341,"kind":"organization","name":"Cascadian Therapeutics, Inc.","symbol":"CASC"},"owners":[{"id":34781,"kind":"person","name":"SPIEGELMAN DANIEL K","position":1,"cik":"0001238403","reported_name":"SPIEGELMAN DANIEL K","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2017-02-10T16:42:37.000Z","date":"2016-06-06","kind":"tax_withholding","acquired":false,"shares":681,"price":7.38,"value":5025.78,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"681 shares (which number reflects post-reverse split shares) of the restricted share unit (\"RSU\") grant, which represent approximately 25% of the shares underlying the RSU grant that vested on June 6, 2016, were not issued to the reporting holder; instead the reporting holder received an amount in cash from the issuer equal to the value of such shares based on the closing price of the issuer's Common Stock on June 6, 2016, the most recent date prior to the vesting date on which the issuer's Common Stock was traded, to facilitate such holder's satisfaction of U.S. federal income tax obligations in connection with the vesting of the RSUs, which transaction does not represent a sale by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"681 shares (which number reflects post-reverse split shares) of the restricted share unit (\"RSU\") grant, which represent approximately 25% of the shares underlying the RSU grant that vested on June 6, 2016, were not issued to the reporting holder; instead the reporting holder received an amount in cash from the issuer equal to the value of such shares based on the closing price of the issuer's Common Stock on June 6, 2016, the most recent date prior to the vesting date on which the issuer's Common Stock was traded, to facilitate such holder's satisfaction of U.S. federal income tax obligations in connection with the vesting of the RSUs, which transaction does not represent a sale by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Effective as of November 29, 2016, the issuer effected a 6-for-1 reverse split of its common stock.  The price above reflects the reverse stock split."}],"balance_after":10821,"source":{"system":"sec-edgar","filing":"0001209191-17-009572","document":"doc5.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1412067/000120919117009572/doc5.xml","form_type":"5"}},{"id":4457145,"issuer":{"id":168341,"kind":"organization","name":"Cascadian Therapeutics, Inc.","symbol":"CASC"},"owners":[{"id":34781,"kind":"person","name":"SPIEGELMAN DANIEL K","position":1,"cik":"0001238403","reported_name":"SPIEGELMAN DANIEL K","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2017-02-10T16:42:37.000Z","date":"2016-06-06","kind":"exercise","acquired":true,"shares":2723,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Effective as of November 29, 2016, the issuer effected a 6-for-1 reverse split of its common stock.  The number of shares above reflects the reverse stock split."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Effective as of November 29, 2016, the issuer effected a 6-for-1 reverse split of its common stock.  The number of shares above reflects the reverse stock split."}],"balance_after":11502,"source":{"system":"sec-edgar","filing":"0001209191-17-009572","document":"doc5.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1412067/000120919117009572/doc5.xml","form_type":"5"}},{"id":4494217,"issuer":{"id":2404,"kind":"organization","name":"BIOMARIN PHARMACEUTICAL INC","symbol":"BMRN"},"owners":[{"id":34781,"kind":"person","name":"SPIEGELMAN DANIEL K","position":1,"cik":"0001238403","reported_name":"SPIEGELMAN DANIEL K","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Financial Officer"}}],"security":"Common Stock","published_at":"2017-01-10T21:50:32.000Z","date":"2017-01-09","kind":"sale","acquired":false,"shares":5000,"price":90,"value":450000.0,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"Trade made pursuant to a 10b5-1 plan executed on November 16, 2016."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"All shares were sold at the same price."}],"balance_after":18100,"source":{"system":"sec-edgar","filing":"0001140361-17-001375","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1048477/000114036117001375/doc1.xml","form_type":"4"}},{"id":4558441,"issuer":{"id":2404,"kind":"organization","name":"BIOMARIN PHARMACEUTICAL INC","symbol":"BMRN"},"owners":[{"id":34781,"kind":"person","name":"SPIEGELMAN DANIEL K","position":1,"cik":"0001238403","reported_name":"SPIEGELMAN DANIEL K","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Financial Officer"}}],"security":"Common Stock","published_at":"2016-11-14T19:02:09.000Z","date":"2016-11-09","kind":"sale","acquired":false,"shares":20000,"price":90.6103,"value":1812206.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price in column 4 is the weighted average price.  The price actually received ranged from $90.18 to $91.305.  The reporting person shall provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price."}],"balance_after":23100,"source":{"system":"sec-edgar","filing":"0001140361-16-086264","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1048477/000114036116086264/doc1.xml","form_type":"4"}},{"id":4558440,"issuer":{"id":2404,"kind":"organization","name":"BIOMARIN PHARMACEUTICAL INC","symbol":"BMRN"},"owners":[{"id":34781,"kind":"person","name":"SPIEGELMAN DANIEL K","position":1,"cik":"0001238403","reported_name":"SPIEGELMAN DANIEL K","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Financial Officer"}}],"security":"Common Stock","published_at":"2016-11-14T19:02:09.000Z","date":"2016-10-31","kind":"grant","acquired":true,"shares":156,"price":68.442,"value":10676.952,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"Represents shares acquired by the reporting person on October 31, 2016, pursuant to the issuer's Employee Stock Purchase Plan."}],"balance_after":43100,"source":{"system":"sec-edgar","filing":"0001140361-16-086264","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1048477/000114036116086264/doc1.xml","form_type":"4"}}]}